Fundraising FoxO2h Ventures — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Stratosvir develops engineered viral immunotherapy treatments for advanced cancers, including prostate cancer, using modified viruses to activate the body's immune system against tumors.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesStevenage, GB
Dr Chris Ullman(CEO)inAntonio Postigo(CSO)in
BoardPriya Mande(Chairman)in
Co-investorsDeep Science Ventures
PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.
BiotechMedical DevicesCambridge, GB
Co-investorsAmadeus Capital PartnersAstellas Venture Management LLCCambridge Angels groupUniversity of Cambridge EnterpriseAmadeus Capital SAParkwalk Advisors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.